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A simple, sensitive and precise reverse phase high performance liquid chromatographic method has been developed for the 
simultaneous estimation of Clopidogrel bisulfate and rivaroxaban in pharmaceutical dosage forms. The combination drug was 
analyzed on BDS hypersil C18, 250mm × 4.6mm, 5µ, Thermo scientific. Mobile phase consisted of  buffer (0.05M KH2PO4 pH 4.0) : 
methanol in the ratio of 30:70 v/v delivered at a flow rate of 1.0 ml / min and wavelength of detection at 220 nm. The retention times 
of Clopidogrel bisulfate and Rivaroxaban were 2.39 min and 4.04 min respectively. The developed method was validated according 
to ICH guidelines. The proposed method can be used for the determination of these drugs in combined dosage forms. 
 
INTRODUCTION 
Clopidogrel bisulfate is  an adenosine diphosphate receptor 
inhibitor that prevents platelets in the blood from sticking 
together  and forming clots. It is routine component of the 
clinical management of patients after acute coronary 
syndrome.It has been reported that this drug would reduce rates 
of major cardiovascular events 1,2. Chemically it is methyl (+)-
(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H) 
acetate sulfate (1:1). The empirical formula of clopidogrel 
bisulfate is C16H16Cl NO2S•H2SO4 and its molecular weight is 
419.9. Clopidogrel bisulfate, USP is a white to off-white 
powder. Clopidogrel bisulfate tablets, contains 97.875 mg of 
clopidogrel bisulfate which is the molar equivalent of 75 mg of 
clopidogrel base 3,4.  Clopidogrel bisulfate is fairly soluble and 
stable in aqueous solution at low pH, however solubility drops 
steeply when the solution of pH is above 3. Clopidogrel 
bisulfate exhibits poor dissolution in the pH range of 4.5 to 
6.85.  
 
On July 1, 2011, the U.S. Food and Drug  Administration 
(FDA) approved Rivaroxaban for prophylaxis of deep vein 
thrombosis (DVT), which may lead to pulmonary embolism 
(PE), in adults undergoing hip and knee replacement surgery6. 
On November 4, 2011,the U.S. FDA approved Rivaroxaban for 
stroke prophylaxis in patients with non – valvular atrial 
fibrillation7. The addition of very low dose anticoagulation 
with Rivaroxaban may represent a new treatment strategy in 
patients with a recent acute coronary syndrome. A recent 
published trial found that a low dose rivaroxaban to optimal 
anti platelate therapy reduces mortality, cardiovascular 
mortality, infaract or stroke without significantly increasing 
fatal bleeding.8 
The chemical name of rivaroxaban is 5-Chloro-N-(((5S)-2-oxo-
3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxzolidin-5-yl)methyl) 
-2-thiophenecarboxamide. It is a white to yellowish powder 
with a molecular weight of 435.89. Rivaroxaban is only 
slightly soluble in organic solvents (e.g. acetone, polyethylene 
glycol 400) and is practically insoluble in water and aqueous 
media with pH 1 – 9 (pH independent 5 – 7 mg/L are soluble at 
25°C . It could be classified as a Class II substance in the 
Biopharmaceutics Classification System (low solubility, high 
permeability)9.  
 
Literature survey reveals colorimetric method, RPHPLC 
method and bio analytical method for estimation of 
Rivaroxaban10-13. Several spectophotometric and high 
performance liquid chromatographic (HPLC) methods have 
been reported for the separation and quantitation of clopidogrel 
or pravastatin in biological fluids and drug product 15–18. 
 
USP states that clopidogrel bisulfate contains not less than 97.0 
% and not more than 101.5% of clopidogrel bisulfate calculated 
on dried basis. Estimation of clopidogrel bisulfate by HPLC 
using phosphate buffer and acetonitrile (75: 25) at 220 nm 
using L 57 column has been described in USP19. Hence it was 
decided to develop HPLC method for combination of 
clopidogrel bisulfate and rivaroxaban mixer and tablets for 
study purpose. Selecting the appropriate detector before 
starting method development is determined by, for example, 
whether one component is being measured requiring single 
detection or whether qualitative analysis is required where 
universal detection would be preferred.20 
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After taking the above into consideration, method development 
should start with the chromatographic separation step which 
requires selecting an HPLC method and optimization of the 
experimental conditions. Nowadays, different approaches to 
HPLC method development are used. Reversed phase – HPLC 
methods are often selected as an initial choice. It is increasingly 
considered the best separation technique to achieve high 
resolution, a short run time and better reproducibility of 
retention time by manipulating the HPLC conditions21,22. The 
applicability of analytical methods is assessed by a validation 
process. Validation is the formal and systematic way to 
demonstrate the suitability of a developed method for testing 
the analyte to provide useful analytical data within defined 
limits23. ICH guidelines Q2A and Q2B,in the Food and Drug 
Administration guidance, and by United States of 
Pharmacopoeia. 
 
 MATERIALS AND METHODS 
A HPLC SPD- 20AT (Shimadzu) equipped with detector SPD-
20AT, pump LC-20AT, injector: Rheodyne injector (20 µl 
Capacity), syringe: Hamilton (25 µl) and chromatographic 
software: Spinchrom was used for the study purpose. Other 
equipments used for the study are pH Meter from Chemiline, 
India, Ultasonicsonicator from Toshcon, Toshniwal process 
instrument pvt. Ltd. Ajmer, Analytical Balance: AX 200 etc. 
 
Chromatographic conditions: 
Column:  BDS hypersil C18, 250mm × 4.6mm, 5µ(particle 
size), Thermo scientific 
Flow rate: 1.0ml/min 
Injection volume: 20µl 
Column Oven temperature: 25°C /Room Temperature 
Wavelength: 220nm 
Run Time: 10 minutes 
 
Preparation of mobile phase: 
Mobile phase is the mixture of 0.05M potassium dihydrogen 
ortho phosphate buffer pH 4.0and methanol in ratio of 30:70. 
  
Preparation of Buffer for mobile phase: 
0.05M potassium di hydrogen ortho phosphate buffer pH 4.0 
was prepared by dissolving 6.8gm potassium dihydrogen 
orthophosphate in 800ml water. This solution was adjusted to 
pH 4.0 with 1% orthophosphoric acid (H3PO4) and make up 
volume up to 1000ml with water.  
 
Preparation of diluent: 
2.99 gm sodium acetate trihydrtae was dissolved in 1000ml of 
water and pH was adjusted to 4.5 with glacial acetic acid.In this 
buffer 2.00 gm SLS was dissolved and mixed well .This pH 4.5 
Acetate buffer with 0.2% SLS was used as final diluents for 
Assay. 
 
Preparation of Blank solution 
10 ml of methanol was taken in 100 ml volumetric flask and 
make up to 100 ml with diluents, this solution is used as blank. 
 
Preparation of standard solution for Assay: 
Standard Stock Preparation: 
22mg Rivaroxaban working standard and 97.8 mg Clopidogrel 
Bisulfate working standard was taken into a 100 ml volumetric 
flask. In this flask 30-70ml methanol was added and sonicated 
for 10 minutes. Once the standards are dissolved make up the 
volume up to 100ml with methanol. 
 
Standard preparation: 
Further 10 ml from the above stock solution was taken into a 
100 ml volumetric flask and volume is made up with diluent. 
This solution is used as std. (22ppm Rivaroxaban, 97.8 ppm 
clopidogrel bisulfate) 
 
Preparation of Stock solution of Test: 
Twenty tablets of clopidrogel bisulfate tablets 75 mg and 
rivaroxaban tablets 20 mg were weighed separately and 
average weight was determined. Tablets of each product were 
triturated in a mortar pestle separately. Accurately weighed 
quantity of tablet powder equivalent to 22 mg rivaroxaban and 
97.8 mg clopidogrel bisulfate transferred in to 100 ml 
volumetric flask. 70 ml methanol was added and sonicated till 
it dissolved completely by maintaining the temperature at 25°C 
and made volume up to the mark with methanol and mixed. 
The solution was filtered with Whatman filter paper 1 filter. 
Initial few ml of filtered solution was discarded and the filtered 
solution was collected in volumetric flask (220ppm 
Rivaroxaban, 978.0 ppm clopidogrel bisulfate). This stock 
solution was used for the preparation of test solution. 
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Preparation of Test Solution: 
10 ml of above stock solution of test was taken separately in to 
100 ml volumetric flask and was diluted up to the mark with 
diluent and mixed. (22 ppm rivaroxaban, 97.8 ppm clopidogrel 
bisulfate) 
 
Figure 1: Standard Solution 
 
Figure 2: Test Solution 
 
Figure 3: Blank Solution 
 
METHOD VALIDATION  
System Precision 
Standard solution was prepared and injected into HPLC system 
for ten replicates.% RSD for the area response was calculated 
for rivaroxaban and clopidogrel bisulfate and was found to be 
less than 1%. 
 
Linearity  
The linearity of the method was determined by preparing a 
standard stock solution from which working solutions were 
prepared by diluting appropriately to yield solutions containing 
50%, 60%, 75%, 85%, 100%, 110%, 125%,135%,145% and 
150% of the standard solution concentration. Each of these 
solutions was then analyzed in duplicate and the peak areas 
obtained for each analyte compound plotted against 
concentration. Correlation coefficient was calculated for both 
the analytes. The ICH guidelines recommend that for the 
establishment of linearity a minimum of five concentrations be 
utilized over the range of 80 to 120 % 24, 25. This method was 
found to be linear over the range tested for all the two 
compounds.  
 
Precision at Linearity 
For precision at linearity; lower and higher concentration 
prescribed under linearity experiment was injected in replicate 
(6 times) into the HPLC system and the precision was 
evaluated at each concentration. Percent relative standard 
deviation (%RSD) for response factor was calculated.  
 
Method Precision 
Six test preparations as per the above method was prepared and 
injected into the HPLC system by following the conditions 
prescribed in the Test method. Assay was calculated in mg and 
in % of label claim of rivaroxaban and clopidogrel bisulfate for 
each of this test preparation. Now average and % RSD of assay 
of these six test preparations was determined.  
 
Accuracy  
The accuracy of the method was determined by recovery 
experiments. Test preparation was done in triplicate by spiking 
active ingredient into the placebo. Percent recovery was 
calculated. The recovery studies were performed in triplicate. 
This standard addition method was performed at 50%, 75%, 
100%, 125%, 150% level and the percentage recovery was 




Robustness of the method was checked by making slight 
deliberate changes in chromatographic conditions. Test 
solutions were prepared in triplicate as per the above method 
and analyzed with changed parameters. Flow rate was changed 
to ± 10%. As per the test procedure flow rate should be 
1.0ml/min. Assay was performed with these test preparations 
with flow rate 1.1ml/min and 0.9ml/min. Assay of these 
triplicate preparations were calculated. Average, standard 
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deviations and % RSD was determined for these three assay 
results. Similarly robustness was performed for temperature ± 
5°C. For temperature change these three test preparations were 
analyzed maintaining column oven temperature at 20°C for -
5°C and 30°C for +5°C. Assay of these triplicate preparations 
were determined. Average, standard deviations and % RSD 
was determined for these three assay results. For change in 
wavelength these three test solutions were injected in the 
HPLC system at ± 5nm. For -5nm select 215nm and for + 5 
select 225nm. Assay of these triplicate preparations were 
determined. Average, standard deviations and % RSD was 
determined for these three assay results.  
 
Robustness was also performed for change in organic phase for 
± 5 %. As per the test method ratio of buffer and methanol 
should be 30:70. To determine robustness for organic phase at 
+5% buffer & methanol ratio was 26.5:73.5 and for -5%, buffer 
& methanol ratio was 33.5:66.5. Three preparations stated 
above were injected in HPLC system with ratio 26.5:73.5 
(+5%) and 33.5:66.5 (-5%). 
 
Ruggedness  
Ruggedness of the proposed analytical method was evaluated 
for variability studies like system variability, analyst 
variability, and column variability. Six test solutions were 
prepared as per the proposed test method and analyzed for each 
of the variability. Precision studies on replicate six samples at 
each of the variables was performed and effect of ruggedness 
parameter was evaluated. Results were compared with method 
precision data obtained under precision studies. 
 
System variability 
Six test preparations were done as per the above test method 
and injected into the two different HPLC systems by the same 
analyst using the same HPLC column. % assay was calculated 
for each of the test preparation. Average assay of six 
preparations and % RSD for six preparations was calculated 
and recorded. This set is considered as set II. This data was 
compared with the data obtained in the method precision data 
(Set I) and overall average, overall standard deviation, overall 
% RSD for twelve determinations was calculated and recorded 
which should be less than 2%.  
 
Analyst variability 
Six test preparations were prepared as per the proposed test 
method by two different analysts by using same HPLC and 
same column and injected into same HPLC systems. % assay 
was calculated for each of the test preparation. Average assay 
of six preparations and %RSD for six preparations was 
calculated and recorded. This set is considered as set III. This 
data was compared with the data obtained in the method 
precision data (Set I) and overall average, overall standard 
deviation, overall % RSD for twelve determinations was 
calculated and   recorded which should be less than 2%.  
 
Column variability 
Six test preparations were done as per the above test method 
and injected into the same HPLC, by the same analyst but using 
different HPLC column. % assay was calculated for each of the 
test preparation. Average assay of six preparations and %RSD 
for six preparations was calculated and recorded. This set is 
considered as set IV. This data was compared with the data 
obtained in the method precision data (Set I) and overall 
average, overall standard deviation, overall % RSD for twelve 
determinations was calculated and   recorded which should be 
less than 2%. 
 
Filter paper Validation 
To perform filter paper validation standard preparation and test 
preparation was done in duplicate. Some portion of stock 
solution of each of the standard and test preparation was 
filtered through Whatman filter paper 1 and some of the test 
preparation was centrifuged. Each of these preparations was 
further diluted as per the test method and injected in HPLC 
system. Assay of centrifuged and filtered solution was 
calculated. For comparison the % difference between average 
response of filtered and unfiltered standard and % assay of 
filtered and centrifuged test solution was calculated.% 
difference between average response of filtered and unfiltered 
standard and %  difference between assay of filtered and 
centrifuged samples shall be NMT 2.0%. 
 
Solution stability 
In order to demonstrate the stability of both standard and 
sample solutions, the solutions were kept at room temperature 
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and refrigerator at 2 – 8°C  and  the standard & samples were 
analyzed at 0hrs,6hrs,12hrs,18hrs, 24 hrs. 
 
Specificity 
To perform the specificity for placebo interference triplicate 
preparations were done as per the proposed method. To prepare 
the solution of placebo, placebo equivalent to 97.8mg 
clopidogrel bisulfate and 22 mg rivaroxaban was taken and 
preparation was done as per the test procedure. 
 
For specificity of as such sample, test preparation was done as 
per the above proposed method and injected in HPLC system 
and % assay was calculated. The peak purity result was also 
determined.  
 
RESULTS AND DISCUSSION 
The retention times of Clopidogrel bisulfate and Rivaroxaban 
were found about 2.39 min and 4.04 min respectively.  
 
Precision: The precision of an analytical procedure expresses 
the closeness of agreement (degree of scatter) between a series 
of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. 
Precision may be considered at three levels: repeatability, 
intermediate precision and reproducibility. The precision of an 
analytical procedure is usually expressed as the variance, 
standard deviation or coefficient of variation of a series of 
measurements. 25 
 
System Precision: For System Precision % RSD values should 
be less than 1%.Current method was obtained precise as % 
RSD for Clopidogrel Bisulfate was obtained 0.734 and for 
Rivaroxaban was 0.948.Which is less than 1%.Hence complies 
the acceptance criteria of System Precision. 
 
Linearity: The linearity of an analytical procedure is its ability 
(within a given range) to obtain test results which are directly 
proportional to the concentration (amount) of analyte in the 
sample as per ICH Q2R125. Linearity of method was performed 
between the concentration range of 50% to 150%. 
The data obtained from the linearity determination experiments 
was subjected to linear regression analysis for both 
Rivaroxaban and Clopidogrel Bisulfate. The correlation 
coefficient for Rivaroxaban was obtained 0.999 and for 
Clopidogrel Bisulfate was also obtained as 0.999 indicating a 
strong correlation between the concentrations of the analytes 
and the peak areas and therefore the method could be applied in 
the assay of these two analyte compounds. It complies with the 
acceptance criteria of linearity. A method to be linear 
correlation coefficient should not be less than 0.999. Hence it is 
concluded that the proposed method was found to be linear in 
this concentration range for both Clopidogrel Bisulfate and 
Rivaroxaban. 
 
Precision at Linearity: The %RSD of Clopidogrel Bisulfate at 
Lower Level was 0.487 and at higher level 0.760. For 
Rivaroxaban at Lower Level was 0.533 and at higher level 
0.596. Which is less than 2%.From the data obtained for the 
developed RP-HPLC method was found to be precise.  
 
Method Precision: Average, SD & % RSD of assay of six test 
preparations for method precision for Clopidogrel Bisulfate 
was calculated. Method is precise because % RSD of these six 
preparations was obtained less than 2.0%. 
 
Accuracy: The accuracy of an analytical procedure expresses 
the closeness of agreement between the value which is 
accepted either as a conventional true value or an accepted 
reference value and the value found. This is sometimes termed 
trueness. 25 Accuracy of the method was indicated by percent 
recovery which was within the range of 99.73 to 101.07 for 
Rivaroxaban and for Clopidogrel bisulfate 100.05 to 101.38 
which indicates that the method is accurate. It complies the 
acceptance criteria that the recovery at each level shall be NLT 
98.0% and NMT 102.0% of the added amount. 
 
Robustness: Robustness of an analytical procedure is a 
measure of its capacity to remain unaffected by small, but 
deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. 25 As stated in 
Robustness Average, SD and % RSD of three test preparations 
was determined for change in flow rate(at +10%, -10% ), 
change in temperature (at+5°C & -5°C),change in 
wavelength(+5nm & -5nm) and change in organic phase (+5% 
& -5%). The data obtained was compared with method 
precision data. Average of triplicate tests were determined 
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which was compared with the average of method precision 
average assay result. For all these test preparation %RSD was 
obtained NMT2%. The % difference between this average 
assay and with method precision average assay was also 
obtained within±2.0%.  
 
For these changes in flow rate, temperature, wavelength and 
organic phase system suitability parameters were found as per 
the acceptance criteria. The % RSD and % difference with 
method precision’s   average assay as % label content in 
triplicate samples were found within acceptance criteria and 
hence it is concluded that the analytical results remain 
unaffected even there is change flow rate, temperature, 
wavelength and organic phase of mobile phase.   
It was also observed that there were no marked changes in 
chromatograms, which demonstrated that the developed RP-
HPLC method is robust. 
 
Ruggedness: Ruggedness was performed for system 
variability, column variability and day variability. 
 
System variability: For system variability overall average, 
overall SD and the overall % RSD of twelve determinations 
(six assay results obtained with method precision assay of set I 
and six assay results obtained with system variability 
preparations of set II) was obtained NMT 2%.The result found 
within acceptance criteria concluding that ,the method is 
rugged for system variability. 
 
Analyst variability: For  analyst variability overall average, 
overall SD and the overall % RSD of twelve determinations 
(six assay results obtained with method precision of set I and 
six assay results obtained with system variability preparations 
of set III) was obtained NMT 2%. The result found within 
acceptance criteria concluding that, the method is rugged for 
analyst variability. 
 
Column variability: For  column variability overall average, 
overall SD and the overall % RSD of twelve determinations 
(six assay results obtained with method precision of set I and 
six assay results obtained with system variability preparations 
of set IV) was obtained NMT 2%.The result found within 
acceptance criteria concluding that, the method is rugged for 
column variability. 
 
Filter paper validation: Filter paper validation was performed 
and it complies with the acceptance criteria. % difference 
between average response of filtered and unfiltered standard 
was obtained NMT 2.0%.% difference between average % 
assay of filtered and centrifuged test solution was  also found  
NMT 2.0%. The results found within acceptance criteria 
showing that filtration does not affect the assay value response 
of standard. Hence it is concluded that the sample filtration by 
whatman filter paper 1 does not affect the result.  
 
Solution stability: The results of solution stability solutions at 
0hrs, 6hrs, 12hrs, 18hrs, 24 hrs. show that, the retention time 
and peak area of Clopidogrel bisulfate and Rivaroxaban 
remained unchanged and no significant degradation within the 
indicated period was observed. This indicates that both 
solutions were stable for at least 24 hours, which is sufficient to 
complete the analytical procedure. 
 
Specificity: Specificity is the ability to assess unequivocally 
the analyte in the presence of components which may be 
expected to be present. Typically these might include 
impurities, degradants, matrix, etc. as per ICH Q2R1. 25 The 
method was specific since excipients/placebo in the 
formulation did not interfere in the estimation of Clopidogrel 
bisulfate and Rivaroxaban.  
 
There were no peaks at the same RT of Clopidogrel bisulfate 
and rivaroxaban in chromatograms of placebo solutions. For as 
such test preparation purity angle was less than purity 
threshold. Hence it could be concluded that as peak purity of 
the principle peak was passed and method is specific. The 
retention times of Clopidogrel bisulfate and rivaroxaban were 
found about 2.39 min and 4.03 min respectively. The proposed 
method was found to be linear in the concentration range of 
50% to 150% for both Clopidogrel bisulfate and Rivaroxaban.  
 
The method was specific since excipients in the formulation 
did not interfere in the estimation of Clopidogrel bisulfate and 
rivaroxaban. Accuracy of the method was indicated by percent 
Recovery which was within the range of 99.75 to 101.07 for 
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Rivaroxaban and for Clopidogrel bisulfate 100.05 to 101.38 
which indicates that the method was accurate. Precision is 
reflected by %RSD values less than 2.Method was obtained as 
Robust  as Flow rate was changed to ± 10%, Temperature ± 
5°C,Wavelength ± 5nm, Organic phase ± 5 % and % RSD was 
obtained less than 2% .Ruggedness was also studied for system 
variability, column variability and analyst variability and 
system was obtained as Rugged. 
 
CONCLUSION 
A fast simple, reliable, precise and robust isocratic reverse 
phase HPLC method with UV detection was developed for the 
simultaneous estimation of Clopidogrel bisulfate and 
Rivaroxaban. The optimized conditions for the separation of 
the two analytes BDS hypersil C18, 250mm × 4.6mm, 5µ, 
Thermo scientific. Mobile phase consisted of buffer (0.05M 
KH2PO4; pH 4.0): methanol in the ratio of 30:70 v/v delivered 
at a flow rate of 1.0 ml / min and wavelength of detection at 
220 nm. The retention times of Clopidogrel bisulphate and 
Rivaroxaban were 2.39 min and 4.04 min respectively. The 
method was validated for precision, specificity, accuracy, 
linearity, solution stability, robustness, ruggedness and filter 
paper validation.  
 
REFERENCES  
1. Jacbson A. K., Platelet ADP receptor antagonist: 
ticlodipine and clopidrogel; Best pract. Res. Clin. 
Haematol 2004, 17 (1),55-64. 
2. Sanjeeva Y, Sivakumar A  and Sameer G. Navalgund; 
Physico-chemical  studies  on  stability of  clopidrogel  
tablet formulations;Int J Pharm Bio Sci 2012 Oct; 3(4): (P) 
433 – 439 
3. USP monograph (Clopidrogel Bisulfate USP 32-NF 27:  
(P) 1992 
4. Pravin B. Cholkeet al; Development and Validation of 
Spectrophotometric Method for Clopidogrel bisulfate in 
pure and in film coated tablet dosage form ; Arch. Appl. 
Sci. Res., 2012, 4 (1):59-64 
5. Zongyun Huang, Ruben Lozano, Robert Francis et.al ; 
Development of a Single  in Vitro Dissolution Method for 
a combination Trilayer Tablet Formulation of Clopidrogel 
and Pravastatin; 12-19 Dissolution Technologies , Feb 
2011. 
6. "Bayer's Xarelto Approved in Canada" (Press release). 
Bayer.  "Bayer’s Novel Anticoagulant Xarelto now also 
approved in the EU". Bayer. 
7. Pinaz A. Kasad, K.S. Muralikrishna; Design and 
Validation of Dissolution Profile of Rivaroxaban by Using  
RP-HPLC Method in Dosage Form. Asian J. Pharm. Ana. 
2013; Vol. 3: Issue 3, Pg 75-78 
8. Fernandez D, Penela D, Heras M ; Contribution of the new 
oral anticoagulant to the treatment of acute coronary 
syndrome; Med Clin (Barc).2012 oct;139 Suppl 2 : 41-5. 
9. CHMP Assessment report for Xarelto: Doc.Ref.: 
EMEA/543519/2008: European Medicine Agency  
Evaluation of Medicines For Human Use) 
10. Satyanarayana PVV et al; New Spectrophotometric 
methods for the quantitative estimation of Rivaroxaban in 
formulations, International Journal of Research and 
Reviews in Pharmacy and Applied science, 611-620. 
11. Harenberg J, Kramer R, Christina G, Svetlana M, et al; 
Determination of rivaroxaban by different factor Xa 
specific chromogenic substrate assays: reduction of 
interassay variability, Journal of Thrombosis and 
Thrombolysis, J  Thromb Thrombolysis.; 32(3): 267–271, 
October 2011. 
12. Satyanarayana PVV et al; RP-HPLC method development 
and validation for the analysis of rivaroxaban in 
pharmaceutical dosage forms, 2 (1), 226-231,2012. 
13. Souri E, MottaghiS, Mohammad Z et al;  Development of 
a Stability-Indicating HPLC Method and a Dissolution 
Test for Rivaroxaban Dosage Forms. Acta 
Chromatographica DOI: 10.1556/1326.2016.28.3.05 
14. Cholke PB., Ahmed R, Chemate SZ  and Jadhav KR; 
Development and Validation of Spectrophotometric 
Method for Clopidogrel bisulfate in pure and in film 
coated tablet dosage form  Arch. Appl. Sci. Res., 2012, 4 
(1):59-64 
15.  Singh S S, Sharma K, Barot D, Mohan P R, Lohray V B.; 
Estimation of carboxylic acid metabolite of clopidogrel in 
Wistar rat plasma by HPLC and its application to a 
pharmacokinetic study. J. Chromatogr. B 2005, 821 (2), 
173–180.  
16. Ksycinska H.; Rudzki P.; Bukowska-Kiliszek, M; 
Determination of clopidogrel metabolite (SR26334) in 




July – September 2015 Volume 3                                       Issue 3  16 
 
Received  17th April 2015 
Revised 18th May 2015 
Accepted  4th June 2015 
J. App. Pharm. Res., 3 (3); 2015: 09 – 16 
human plasma by LC–MS. J. Pharm. Biomed. Anal. 
2006,41 (2), 533–539. 
17.  Gomez Y; Adams E; Hoogmartens J; Analysis of purity in 
19 drug product tablets containing clopidogrel: 18 copies 
versus the original brand. J. Pharm. Biomed.Anal. 2004,34 
(2), 341–348. 
18. Mitakos A,Panderi I; A validated LC method for the 
determination of clopidogrel in pharmaceutical  
preparations. J. Pharm. Biomed. Anal. 2002, 28 (3–4), 
431–438. 
19. USP monograph Clopidrogel Bisulfate ;USP 32-NF 27:  
(P) 1992 
20. SnyderLR, GlajchJL, KirklandJJ. Practical HPLC Method 
Development. New York: John Wiley:1988,227-251 
21. Majors RE, Prazybeciel M ; Columns for reversed- phase 
LC separation in highly aqueous mobile phases, LCGC 


























22. Wang IH, Moorman R, Burleson J; Isocratic reversed 
phase  liquid chromatographic method for the 
simultaneous determination of (s) Methoprene, MGK 264, 
Piperronylbutoxide, sumitrhin, and permethrin in pesticide 
formulation; J Chormatogr A 2003 Jan 3,983(1-2):145-52  
23. Maldener G,  Chromatographia 1989,28,85-88 
24. ICH Harmonized Tripartite Guideline Q2B: Text on 
Validation of Analytical Procedures: Methodology, ICH 
Steering Committee, 1994. www.scribd.com/doc/.../ICH-
Validation-of-Analytical-Procedures  
25. International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use: ICH Triplicate Guidelines, validation of 
analytical procedures: text and methodology. Q (R1), 
2005.  
 
 
